文献速递泌尿男性生殖肿瘤

通过抗体递送靶向前列腺特异性膜抗原的α发射体治疗转移性去势抵抗性前列腺癌:225Ac-J591的I期剂量递增研究

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.
PubMed 文献 · J Clin Oncol · 2023-11-03

该I期剂量递增研究在32例经治进展性转移性去势抵抗性前列腺癌(mCRPC)患者中评估单次225Ac-J591的安全性与疗效,未进行PSMA筛选。未达到最大耐受剂量,推荐II期剂量为最高剂量水平93.3 KBq/kg;46.9%患者出现至少50%的前列腺特异性抗原(PSA)下降,22例中13例(59.1%)达到方案定义的循环肿瘤细胞(CTC)计数反应。

要点

  • 32例经治进展性mCRPC患者接受单次225Ac-J591,未达到最大耐受剂量。
  • 推荐II期剂量为最高剂量水平93.3 KBq/kg。
  • 46.9%患者出现至少50%的PSA下降,22例中13例(59.1%)达到CTC计数反应。

核心结论

  • 据作者所知,这是首个人体I期剂量递增试验,在32例经治进展性mCRPC患者中证实单次225Ac-J591具有安全性和初步疗效信号。
  • 进一步研究正在进行中。

研究设计与样本

  • I期剂量递增研究,采用加速剂量递增设计,共32例患者接受225Ac-J591,其中剂量递增阶段22例,扩展阶段10例。
  • 入组患者为经治进展性mCRPC,对标准治疗无效或拒绝标准治疗,包括雄激素受体通路抑制剂,且已接受或被认为不适合紫杉烷类化疗。
  • 未进行PSMA筛选;患者接受单次225Ac-J591,剂量递增共七个水平,随后在最高剂量进行扩展。
  • 剂量递增队列的主要终点为剂量限制性毒性(DLT)和推荐II期剂量(RP2D)的确定。

主要发现

  • 1例患者(22例中1例;4.5%)在第6队列(80 KBq/kg)发生DLT,第7队列无DLT发生;未达到最大耐受剂量,RP2D为最高剂量水平93.3 KBq/kg。
  • 多数高级别不良事件为血液学毒性,与给予的放射性活度似有关联;非血液学不良事件一般为低级别。
  • 46.9%的患者在任何时间出现至少50%的PSA下降,34.4%为确认的PSA反应。
  • 方案定义的CTC计数反应发生于22例中的13例(59.1%)。

临床怎么用

  • 作者认为,单次225Ac-J591在经治进展性mCRPC中显示出安全性和初步疗效信号,进一步研究正在进行中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) for 225Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225. METHODS: Following investigational new drug-enabling preclinical studies, we enrolled patients with progressive mCRPC that was refractory to or who refused standard treatment options (including androgen receptor pathway inhibitor and had received or been deemed ineligible for taxane chemotherapy). No selection for PSMA was performed. Patients received a single dose of 225Ac-J591 at one of seven dose-escalation levels followed by expansion at the highest dose. Primary end point of dose-escalation cohort was determination of dose-limiting toxicity (DLT) and RP2D. RESULTS: Radiochemistry and animal studies were favorable. Thirty-two patients received 225Ac-J591 in an accelerated dose-escalation design (22 in dose escalation, 10 in expansion). One patient (1 of 22; 4.5%) experienced DLT in cohort 6 (80 KBq/kg) but none in cohort 7; MTD was not reached, and RP2D was the highest dose level (93.3 KBq/kg). The majority of high-grade adverse events (AEs) were hematologic with an apparent relationship with administered radioactivity. Nonhematologic AEs were generally of low grade. Prostate-specific antigen (PSA) declines and circulating tumor cell (CTC) control were observed: 46.9% had at least 50% PSA decline at any time (34.4% confirmed PSA response), and protocol-defined CTC count response occurred in 13 of 22 (59.1%). CONCLUSION: To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals. Further investigation is underway.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tagawa ST, Thomas C, Sartor AO, et al. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591. J Clin Oncol. 2023. PMID: 37922438. doi:10.1200/JCO.23.00573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。